Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11138975 | 0.90 | SLC6A4 (0.45) | ITGB3ITGA2BNFE2L2TDP1CHEK2 | |
| SCHEMBL1697752 | 0.88 | NFE2L2 (0.56) | NFE2L2TDP1KDM4ERECQL | |
| SCHEMBL4326032 | 0.83 | NPY1R (0.50) | ITGB3ITGA2BNFE2L2TDP1CHEK2 | |
| SCHEMBL13144645 | 0.83 | TDP1 (0.51) | ITGB3ITGA2BNFE2L2TDP1CHEK2 | |
| SCHEMBL4329812 | 0.83 | ITGB3 (0.49) | ITGB3ITGA2BNFE2L2TDP1CHEK2 | |
| SCHEMBL13335378 | 0.83 | ITGB3 (0.52) | ITGB3ITGA2BNFE2L2TDP1CHEK2 | |
| SCHEMBL15651091 | 0.83 | NFE2L2 (0.71) | ITGB3ITGA2BNFE2L2TDP1CHEK2 | |
| SCHEMBL23163613 | 0.83 | NFE2L2 (0.70) | NFE2L2TDP1KDM4ERECQL | |
| SCHEMBL2460394 | 0.83 | TDP1 (0.68) | ITGB3ITGA2BTDP1KDM1AEP300 | |
| SCHEMBL1334281 | 0.83 | ITGB3 (0.51) | ITGB3ITGA2BNFE2L2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026258-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2011-09-27 | — | — | US | disclosed |
| US-20100120845-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-05-13 | — | — | US | disclosed |
| US-7674805-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-03-09 | — | — | US | disclosed |
| US-20080312262-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-12-18 | — | — | US | disclosed |
| US-7439257-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2008-10-21 | — | — | US | disclosed |
| EP-1708994-B1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2007-08-08 | — | — | EP | disclosed |
| US-20070021424-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
| EP-1708994-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005077898-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021424-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | CMBL, ALK, ALKBH1 | ITGB3 1452/4885ITGA2B 670/4885NFE2L2 2661/4885 |
| US-20100120845-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | CMBL, ALK, ALKBH1 | ITGB3 1452/4885ITGA2B 670/4885NFE2L2 2661/4885 |
| US-20080312262-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | CMBL, ALK, ALKBH1 | ITGB3 1452/4885ITGA2B 670/4885NFE2L2 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.